Is FibroGen Stock a Good Investment?
FibroGen Investment Advice | FGEN |
- Examine FibroGen's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research FibroGen's leadership team and their track record. Good management can help FibroGen navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact FibroGen's business and its evolving consumer preferences.
- Compare FibroGen's performance and market position to its competitors. Analyze how FibroGen is positioned in terms of product offerings, innovation, and market share.
- Check if FibroGen pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about FibroGen's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in FibroGen stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if FibroGen is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine FibroGen Stock
Researching FibroGen's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.23. FibroGen had not issued any dividends in recent years. The entity had 1:1 split on the September 8, 2009.
To determine if FibroGen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding FibroGen's research are outlined below:
| FibroGen had very high historical volatility over the last 90 days | |
| FibroGen has some characteristics of a very speculative penny stock | |
| FibroGen has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 147.75 M. Net Loss for the year was (284.23 M) with loss before overhead, payroll, taxes, and interest of (159.21 M). | |
| FibroGen currently holds about 438.13 M in cash with (315.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| FibroGen has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Bluejay Therapeutics Announces Expansion of Leadership Team andBoard of Directors |
FibroGen Quarterly Cost Of Revenue |
|
FibroGen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in FibroGen. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to FibroGen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact FibroGen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises FibroGen's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-06 | 2024-03-31 | -0.42 | -0.33 | 0.09 | 21 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 | ||
2015-08-13 | 2015-06-30 | 0.73 | 0.83 | 0.1 | 13 | ||
2016-05-09 | 2016-03-31 | -0.56 | -0.45 | 0.11 | 19 | ||
2017-11-08 | 2017-09-30 | -0.37 | -0.5 | -0.13 | 35 | ||
2019-05-09 | 2019-03-31 | -0.67 | -0.53 | 0.14 | 20 | ||
2024-02-26 | 2023-12-31 | -0.42 | -0.57 | -0.15 | 35 | ||
2022-05-09 | 2022-03-31 | -0.83 | -0.68 | 0.15 | 18 |
Know FibroGen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as FibroGen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading FibroGen backward and forwards among themselves. FibroGen's institutional investor refers to the entity that pools money to purchase FibroGen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-09-30 | 767.7 K | Renaissance Technologies Corp | 2024-09-30 | 753.1 K | Two Sigma Advisers, Llc | 2024-09-30 | 742.8 K | Two Sigma Investments Llc | 2024-09-30 | 505.5 K | Jane Street Group Llc | 2024-06-30 | 450 K | Fmr Inc | 2024-09-30 | 383.3 K | State Street Corp | 2024-09-30 | 342.2 K | Lmr Partners Llp | 2024-09-30 | 249.5 K | Vantage Consulting Group Inc. | 2024-09-30 | 195.7 K | Primecap Management Company | 2024-09-30 | 9.9 M | Armistice Capital, Llc | 2024-09-30 | 6.8 M |
FibroGen's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.42 M.Market Cap |
|
FibroGen's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.64) | |
| Return On Capital Employed | (1.37) | (1.30) | |
| Return On Assets | (0.67) | (0.64) | |
| Return On Equity | 1.39 | 0.74 |
Determining FibroGen's profitability involves analyzing its financial statements and using various financial metrics to determine if FibroGen is a good buy. For example, gross profit margin measures FibroGen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of FibroGen's profitability and make more informed investment decisions.
Evaluate FibroGen's management efficiency
FibroGen has return on total asset (ROA) of (0.2655) % which means that it has lost $0.2655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.3. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 3rd of December 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.67) | (1.58) | |
| Tangible Book Value Per Share | (1.67) | (1.58) | |
| Enterprise Value Over EBITDA | (0.55) | (0.52) | |
| Price Book Value Ratio | (0.42) | (0.40) | |
| Enterprise Value Multiple | (0.55) | (0.52) | |
| Price Fair Value | (0.42) | (0.40) | |
| Enterprise Value | 164.5 M | 156.2 M |
FibroGen benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta 0.726 |
Basic technical analysis of FibroGen Stock
As of the 3rd of December, FibroGen shows the Semi Deviation of 5.44, downside deviation of 7.04, and Mean Deviation of 4.83. FibroGen technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.FibroGen's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases FibroGen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
FibroGen's Outstanding Corporate Bonds
FibroGen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. FibroGen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most FibroGen bonds can be classified according to their maturity, which is the date when FibroGen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Fidelity Guaranty Life Corp BondUS315786AC73 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand FibroGen's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing FibroGen's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0555 | |||
| Market Risk Adjusted Performance | 0.2276 | |||
| Mean Deviation | 4.83 | |||
| Semi Deviation | 5.44 | |||
| Downside Deviation | 7.04 | |||
| Coefficient Of Variation | 1635.34 | |||
| Standard Deviation | 6.48 | |||
| Variance | 42.05 | |||
| Information Ratio | 0.042 | |||
| Jensen Alpha | 0.1835 | |||
| Total Risk Alpha | (0.58) | |||
| Sortino Ratio | 0.0387 | |||
| Treynor Ratio | 0.2176 | |||
| Maximum Drawdown | 36.6 | |||
| Value At Risk | (9.76) | |||
| Potential Upside | 11.9 | |||
| Downside Variance | 49.5 | |||
| Semi Variance | 29.55 | |||
| Expected Short fall | (6.30) | |||
| Skewness | 0.383 | |||
| Kurtosis | 1.02 |
| Risk Adjusted Performance | 0.0555 | |||
| Market Risk Adjusted Performance | 0.2276 | |||
| Mean Deviation | 4.83 | |||
| Semi Deviation | 5.44 | |||
| Downside Deviation | 7.04 | |||
| Coefficient Of Variation | 1635.34 | |||
| Standard Deviation | 6.48 | |||
| Variance | 42.05 | |||
| Information Ratio | 0.042 | |||
| Jensen Alpha | 0.1835 | |||
| Total Risk Alpha | (0.58) | |||
| Sortino Ratio | 0.0387 | |||
| Treynor Ratio | 0.2176 | |||
| Maximum Drawdown | 36.6 | |||
| Value At Risk | (9.76) | |||
| Potential Upside | 11.9 | |||
| Downside Variance | 49.5 | |||
| Semi Variance | 29.55 | |||
| Expected Short fall | (6.30) | |||
| Skewness | 0.383 | |||
| Kurtosis | 1.02 |
Consider FibroGen's intraday indicators
FibroGen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of FibroGen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
FibroGen time-series forecasting models is one of many FibroGen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary FibroGen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
FibroGen Stock media impact
Far too much social signal, news, headlines, and media speculation about FibroGen that are available to investors today. That information is available publicly through FibroGen media outlets and privately through word of mouth or via FibroGen internal channels. However, regardless of the origin, that massive amount of FibroGen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of FibroGen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of FibroGen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to FibroGen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive FibroGen alpha.
FibroGen Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards FibroGen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
FibroGen Corporate Management
| Kirk MBA | Chief Officer | Profile | |
| Rahul Kaushik | Technical Development | Profile | |
| Mr JD | Chief Officer | Profile | |
| Enrique Conterno | CEO Director | Profile | |
| Barry Berkowitz | Founder | Profile | |
| Christine Chung | Senior Operations | Profile | |
| David DeLucia | Vice Relations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share 1.758 | Quarterly Revenue Growth 0.143 | Return On Assets (0.27) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between FibroGen's value and its price, as these two are different measures arrived at by various means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.